David joined Sofinnova as Executive Partner in 2007. He represents Sofinnova as the Chairman of NextCure, and as Director of Antiva Biosciences, Dauntless Pharmaceuticals, Rainier Therapeutics and Neurana. He also serves as Chairman of Lineagen and as a Director of bioTheranostics and Castle Biosciences. Previously he served as the Chairman of both Trius Therapeutics and Amplimmune, and as a Director of InterMune and Principia.
Prior to Sofinnova, David spent almost 30 years in industry leading technology and product development programs in the pharmaceutical, biopharmaceutical, and drug delivery fields. David co-founded Salmedix, a developer of cancer drug treatments, and served as the company’s Chairman and Chief Executive Officer until its acquisition of Salmedix by Cephalon. David also held the positions of Executive Vice President of Dura, a specialty pharmaceutical and pulmonary drug delivery company, and President and Chief Executive Officer of Spiros Development. Earlier, David was Chief Executive Officer of Corvas International and held senior executive positions with Hybritech.
David received his PhD from Yale University and his BA from Case Western Reserve University.